StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie AbbVie Share of Venclexta R&D Collaboration Costs by Year

AbbVie Share of Venclexta R&D Collaboration Costs [annual] ($M) ($M)

AbbVie AbbVie Share of Venclexta R&D Collaboration Costs: $63M in FY2025, down 25.0% from a year earlier. That is the lowest of the 8 years on record here.

Latest, FY2025
63
Period ended Dec 31, 2025
Change on a year earlier
-25.0%
84 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-K Note 5 Licensing, Acquisitions & Other Arrangements.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAbbVie Share of Venclexta R&D Collaboration Costs [annual] ($M) ($M)Year on yearSource
FY2025Dec 31, 202563-25.0%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 202484-22.9%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023109-9.9%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 2022121-13.6%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021140+8.5%Form 10-K (filed 2024-02-20) ↗
FY2020Dec 31, 2020129+0.8%Form 10-K (filed 2023-02-17) ↗
FY2019Dec 31, 2019128-20.0%Form 10-K (filed 2022-02-18) ↗
FY2018Dec 31, 2018160–Form 10-K (filed 2021-02-19) ↗

Cite this data

StockData. (2026). AbbVie AbbVie Share of Venclexta R&D Collaboration Costs ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/collab-genentech-rd

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.